↓ Skip to main content

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors

Overview of attention for article published in Frontiers in oncology, December 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
9 Mendeley